These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11000464)

  • 1. Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections.
    Kyd J; Cripps A
    J Biotechnol; 2000 Sep; 83(1-2):85-90. PubMed ID: 11000464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal vaccination against bacterial respiratory infections.
    Baumann U
    Expert Rev Vaccines; 2008 Oct; 7(8):1257-76. PubMed ID: 18844598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal immunization against respiratory bacterial pathogens.
    Foxwell AR; Kyd JM; Cripps AW
    Expert Rev Vaccines; 2003 Aug; 2(4):551-60. PubMed ID: 14711339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges.
    Murphy TF
    Expert Rev Vaccines; 2005 Dec; 4(6):843-53. PubMed ID: 16372880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal vaccines for protection against respiratory and systemic bacterial infections.
    Oliveira ML; Arêas AP; Ho PL
    Expert Rev Vaccines; 2007 Jun; 6(3):419-29. PubMed ID: 17542756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoproteomics: the key to discovery of new vaccine antigens against bacterial respiratory infections.
    Dennehy R; McClean S
    Curr Protein Pept Sci; 2012 Dec; 13(8):807-15. PubMed ID: 23305366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current progress with Moraxella catarrhalis antigens as vaccine candidates.
    Mawas F; Ho MM; Corbel MJ
    Expert Rev Vaccines; 2009 Jan; 8(1):77-90. PubMed ID: 19093775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of infections of the respiratory tract using the oral application of antigens.
    Tischner H
    Z Erkr Atmungsorgane; 1991; 176(2-3):131-7. PubMed ID: 1858413
    [No Abstract]   [Full Text] [Related]  

  • 9. Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae.
    Lee HY; Andalibi A; Webster P; Moon SK; Teufert K; Kang SH; Li JD; Nagura M; Ganz T; Lim DJ
    BMC Infect Dis; 2004 May; 4():12. PubMed ID: 15125783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Pneumococcal Conjugate Vaccine on the Natural Antibodies and Antibody Responses Against Protein Antigens From Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Children With Community-acquired Pneumonia.
    Andrade DC; Borges IC; Adrian PV; Meinke A; Barral A; Ruuskanen O; Käyhty H; Nascimento-Carvalho CM
    Pediatr Infect Dis J; 2016 Jun; 35(6):683-9. PubMed ID: 26954601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential impact of a Moraxella catarrhalis vaccine in COPD.
    Perez AC; Murphy TF
    Vaccine; 2019 Sep; 37(37):5551-5558. PubMed ID: 28185742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine targets against Moraxella catarrhalis.
    Ren D; Pichichero ME
    Expert Opin Ther Targets; 2016; 20(1):19-33. PubMed ID: 26565427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on non-typeable Haemophilus influenzae-mediated disease and vaccine development.
    Jalalvand F; Riesbeck K
    Expert Rev Vaccines; 2018 Jun; 17(6):503-512. PubMed ID: 29863956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems and progress towards vaccination against bacterial infections of the respiratory tract.
    Artenstein MS
    Dev Biol Stand; 1975; 28():115-25. PubMed ID: 236208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the development and use of viral and bacterial vaccines for the prevention of acute otitis media.
    Greenberg DP
    Allergy Asthma Proc; 2001; 22(6):353-7. PubMed ID: 11775392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview.
    Kyd JM; Cripps AW
    Vaccine; 1999 Mar; 17(13-14):1775-81. PubMed ID: 10194839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nontypeable Haemophilus influenzae: challenges in developing a vaccine.
    Kyd J; Cripps A
    J Biotechnol; 1999 Aug; 73(2-3):103-8. PubMed ID: 10486920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nontypeable Haemophilus influenzae (NTHi) epidemiology].
    Sunakawa K; Takeuchi Y; Iwata S
    Kansenshogaku Zasshi; 2011 May; 85(3):227-37. PubMed ID: 21706841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against middle-ear bacterial and viral pathogens.
    Giebink GS
    Ann N Y Acad Sci; 1997 Dec; 830():330-52. PubMed ID: 9616694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in children with acute respiratory infection with or without nasopharyngeal bacterial carriage.
    Andrade DC; Borges IC; Bouzas ML; Oliveira JR; Käyhty H; Ruuskanen O; Nascimento-Carvalho C
    Infect Dis (Lond); 2018 Sep; 50(9):705-713. PubMed ID: 29688138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.